Search for grants with us!
Grants you might be eligible for
Accelerating the Pace of Substance Use Research Using Existing Data
RFA-DA-26-056
Programme: NIH Grants
General Overview
Organizational Aspects
Funding
Up to 275000.00 USD
Deadline
Dec. 3, 2025, 10 p.m.
Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
PAR-25-037
Up to 200000.00 USD
June 16, 2026, 10 p.m.
Innovation Grants to Nurture Initial Translational Efforts (IGNITE)
PAR-25-060
Programme: NIH IGNITE Program
Up to 499000.00 USD
Oct. 20, 2027, 10 p.m.
Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders
PAR-24-267
Up to 250000.00 USD
July 28, 2025, 10 p.m.
Bidirectional Influences Between Adolescent Social Media Use and Mental Health (R21 Clinical Trial Optional)
RFA-MH-25-206
Oct. 20, 2025, 10 p.m.
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders
PAR-25-184
Programme: National Institutes of Health (NIH)
Up to None USD
Feb. 17, 2027, 10 p.m.
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
PAR-25-226
GRANT OVERVIEW
ELIGIBILITY CRITERIA
Nov. 19, 2026, 10 p.m.
Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)
PAR-25-055
June 22, 2026, 10 p.m.
Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes
PAR-25-206
Programme: NIH Research Project Grant
Up to 750000.00 USD
Oct. 5, 2027, 10 p.m.
Novel Mechanism Research on Neuropsychiatric Symptoms in Alzheimer's Dementia
PAR-25-064
Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
PAR-25-158
Up to 500000.00 USD
Nov. 18, 2026, 10 p.m.
NIAID Clinical Trial Implementation Cooperative Agreement (U01)
PAR-24-100
Programme: NIAID Clinical Trial Implementation
Jan. 13, 2027, 10 p.m.
Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)
PAR-23-060
Up to 450000.00 USD
Jan. 9, 2026, 10 p.m.
Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases
PAR-23-032
Programme: Small Business Innovation Research (SBIR)
Up to 2000000.00 USD
Sept. 5, 2025, 10 p.m.
Centers for AIDS Research (P30 Clinical Trial Not Allowed)
PAR-23-116
Programme: Centers for AIDS Research
Up to 3250000.00 USD
Aug. 5, 2025, 5 p.m.
Avenir Award Program for Research on Substance Use Disorders and HIV
PAR-23-125
Programme: NIH Director’s New Innovator Awards
Up to 1500000.00 USD
Aug. 16, 2025, 10 p.m.
Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)
PAS-22-196
Up to 2500000.00 USD
Sept. 5, 2025, 5 p.m.
Commercial Fishing Occupational Safety Research Cooperative Agreement (U01)
RFA-OH-22-005
Programme: CDC and NIOSH Funding
Up to 975000.00 USD
Jan. 26, 2027, 10 p.m.
NIDA Research Center of Excellence Grant Program
PAR-23-076
Programme: NIDA Research Center of Excellence Grant Program
Up to 10000000.00 USD
Sept. 25, 2025, 10 p.m.
BRAIN Initiative: Exploratory Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain
RFA-DC-24-001
Programme: BRAIN Initiative
Up to 700000.00 USD
Sept. 19, 2025, 10 p.m.
440 results. Page 6 of 22.